binding affinity News and Research

RSS

RNA-dependent RNA polymerase inhibitors in COVID-19 therapy

A new paper reviews current knowledge of RdRp inhibitors that could be developed further to provide broadly effective antivirals against SARS-CoV-2 in particular and CoVs in general.

10 Oct 2022

PSI researchers optimize a method for tumor diagnosis using radionuclides

Researchers at the Paul Scherrer Institute PSI, in collaboration with ETH Zurich, have optimized a method for tumor diagnosis using radionuclides.

5 Oct 2022

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

30 Sep 2022

Bioactive compounds derived from Ganoderma lucidum exhibit anti-SARS-CoV-2 activity

Scientists have identified lucidenic acid A, one of the bioactive compounds of Ganoderma lucidum, as a potential inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell entry. The study has recently been published in the journal Food and Chemical Toxicology.

29 Sep 2022

Researchers computationally design immunogens to elicit antibodies against different SARS-CoV-2 variants

A recent study designed immunogens to induce antibodies against SARS-CoV-2 variants.

28 Sep 2022

Q-LAAD: a dynamic, cost-effective rapid antigen test for detection of SARS-CoV-2

Researchers developed a high-throughput, rapid antigen SARS-CoV-2 spike protein detection test using allonamers, a new type of aptamers that carry out allosteric regulation instead of catalytic activity.

28 Sep 2022

Omicron BA.1 breakthrough infection in vaccinated individuals recall memory B cells to confer immunity

In a new study, researchers followed up with individuals vaccinated with a COVID-19 vaccine based on the mRNA platform up to six months following Omicron BA.1 breakthrough infection to trace the evolution of their antibody immunity.

26 Sep 2022

DNA nets effectively target the spike protein and detect COVID-19 virus at very low levels

Tiny nets woven from DNA strands can ensnare the spike protein of the virus that causes COVID-19, lighting up the virus for a fast-yet-sensitive diagnostic test – and also impeding the virus from infecting cells, opening a new possible route to antiviral treatment, according to a new study.

23 Sep 2022

Deep mutational scanning for SARS-CoV-2 Omicron BA.1 and BA.2 subvariants

Researchers performed deep mutational scanning for the SARS-CoV-2 Omicron variant of concern sub-VOC BA.1 and BA.2 receptor-binding domains.

22 Sep 2022

What is the efficacy of aerosol treatment for SARS-CoV-2 infection?

In a new study, researchers assessed the efficacy of the scFv76 antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lung damage.

21 Sep 2022

Molecular engineered low-cost highly effective RBD-based COVID vaccine

In a recent study posted to the bioRxiv* preprint server, an international team of researchers developed a second-generation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor binding domain (RBD) antigen (RBD-J6) by molecular engineering with two additional amino acid (aa) substitutions (S383D and L518D mutations) in a hydrophobic cryptic RBD core epitope to enhance stability and expression against SARS-CoV-2 variants of concern (VOCs).

19 Sep 2022

Lab experiments add further evidence to the bradykinin storm theory of COVID-19’s viral pathogenesis

A new paper published in Nature Communications adds further evidence to the bradykinin storm theory of COVID-19's viral pathogenesis - a theory that was posited two years ago by a team of researchers at the Department of Energy's Oak Ridge National Laboratory.

16 Sep 2022

SARS-CoV-2 N escape mutations do not affect rapid antigen testing

A new study maps the escape mutations found in various strains of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could cause them to escape neutralization by antibodies or detection by rapid antigen tests that rely on antibody binding for a positive result.

16 Sep 2022

Development of improved monoclonal antibodies against SARS-CoV-2

In a new study, researchers explored strategies for the development of effective monoclonal antibodies (mAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2022

What is the impact of COVID-19 treatments targeting intracellular Neu1?

In a new study, researchers assessed the impact of targeting intracellular Neu1 on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

14 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Scientists observe how SARS-CoV-2 protein dismantles critical immunity pathway

Over the past two years, scientists have studied the SARS-CoV-2 virus in great detail, laying the foundation for developing COVID-19 vaccines and antiviral treatments.

9 Sep 2022

The use of AlphaFold2-enabled molecular docking simulations to predict protein-ligand interactions for antibiotic drug discovery

Researchers demonstrated that advances in modeling protein-ligand interactions using machine learning-based approaches are needed to exploit AlphaFold2 for antibiotic discovery better.

9 Sep 2022

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

A recent PLoS ONE study detected neutralizing nanobodies against SARS-CoV-2 from nanobody phage display libraries and via in vitro and ex vivo high-throughput screenings.

2 Sep 2022

Intranasally delivered neutralizing antibody protects against SARS-CoV-2 Omicron and Delta variants

The current study focused on the ability of this nmAb to neutralize Delta, Omicron, and other VOCs, as well as its efficacy when given by the intranasal route in an animal model.

1 Sep 2022